A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: Results from the CONKO-005 trial
Background: high recurrence rates of up to 75% within 2 years in pancreatic ductal adenocarcinoma (PDAC) patients resected for cure indicate a high medical need for clinical prediction tools and patient specific treatment approaches. Addition of the EGFR inhibitor erlotinib to adjuvant chemotherapy...
Main Authors: | K. Hoyer, R. Hablesreiter, Y. Inoue, K. Yoshida, F. Briest, F. Christen, N. Kakiuchi, T. Yoshizato, Y. Shiozawa, Y. Shiraishi, J.K. Striefler, S. Bischoff, P. Lohneis, H. Putter, O. Blau, U. Keilholz, L. Bullinger, U. Pelzer, M. Hummel, H. Riess, S. Ogawa, M. Sinn, F. Damm |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-04-01
|
Series: | EBioMedicine |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2352396421001201 |
Similar Items
-
Sustained Response of a Clivus Chordoma to Erlotinib after Imatinib Failure
by: Aline Houessinon, et al.
Published: (2015-01-01) -
Erlotinib in the Second/Third Line Treatment of Patients with Advanced Non-small Cell Lung Cancer
by: Yilong WU, et al.
Published: (2009-05-01) -
Mucin-1 Protein Is a Prognostic Marker for Pancreatic Ductal Adenocarcinoma: Results From the CONKO-001 Study
by: Jana Käthe Striefler, et al.
Published: (2021-07-01) -
Modified Synthesis of Erlotinib Hydrochloride
by: Leila Barghi, et al.
Published: (2012-06-01) -
A rapid and convenient method for synthesis of anilinoquinazoline: an improved synthesis of erlotinib derivatives
by: Zahra Haghighijoo, et al.
Published: (2015-09-01)